The FDA has released new drug rejection letters after a pause in its transparency policy, with some reports indicating a temporary suspension had been in place. The release of these letters, which disclose why certain drugs are not approved, has resumed with 14 new letters being made public. The policy's impact on pharmaceutical companies is a point of contention, with some expressing concerns about its effects on business.